FIELD: chemistry.
SUBSTANCE: invention relates to biochemistry, in particular to an anti-CD47 antibody or its antigen-binding fragment, as well as to a pharmaceutical composition and a kit containing it. Also disclosed is a nucleic acid coding said antibody or its fragment, as well as a vector and a cell containing it.
EFFECT: invention is effective for treating a CD47-positive tumour.
25 cl, 13 dwg, 4 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIGEN-BINDING POLYPEPTIDE BINDING TO CD47, AND USE THEREOF | 2021 |
|
RU2833294C2 |
| CD47-ANTIGEN-BINDING UNIT AND ITS USE | 2018 |
|
RU2780859C2 |
| ANTI-SIRPα ANTIBODIES | 2018 |
|
RU2771174C2 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
| ANTIBODIES SPECIFIC TO CD47 AND PD-L1 | 2020 |
|
RU2779652C2 |
| FUNCTION PROTEIN AND ITS USE | 2019 |
|
RU2800923C2 |
| Therapeutic antibodies to CD47 | 2016 |
|
RU2748401C2 |
| ANTIBODIES AGAINST CD40 AND THEIR USE | 2018 |
|
RU2796413C2 |
| FUSION PROTEIN AND ITS USE | 2020 |
|
RU2811120C2 |
